HBV-DNA level at 6 months of entecavir treatment predicts HBeAg loss in HBeAg-positive chronic hepatitis B patients
Journal
Journal of the Formosan Medical Association
Journal Volume
114
Journal Issue
4
Pages
308-313
Date Issued
2015
Author(s)
Peng C.-Y.
Hsieh T.-C.
Hsieh T.-Y.
Tseng K.-C.
Lin C.-L.
Lin H.H.
Wang C.-C.
Abstract
Background/Purpose: To evaluate whether on-treatment HBV-DNA level could predict the treatment response to entecavir in hepatitis B e antigen (HBe)-positive chronic hepatitis B (CHB) patients. Methods: A total of 68 treatment-na?ve HBeAg-positive patients (75% male, mean age at 46.6±11.9 years) receiving at least 2 years of entecavir therapy were enrolled. The primary therapeutic endpoint was HBeAg loss. On-treatment complete virological response was defined as serum HBV-DNA<63IU/mL. Results: The median baseline alanine aminotransferase (ALT) and HBV-DNA levels were 199.5 (27-1622) U/L and 7.7 (3.8-13.2) log10IU/mL, respectively. The median treatment duration was 31.7 (24.3-69.6) months. The rate of HBeAg loss at 2 years was 30.9%. By univariate analysis, on-treatment complete virological response at Month 6 was associated with HBeAg loss at 2 years (p=0.019). After adjustment for age, sex, cirrhosis, baseline ALT, and HBV-DNA levels, this factor remained significant in multivariate analysis (odds ratio: 4.35; 95% confidence interval: 1.24-15.24, p=0.021). Conclusion: On-treatment complete virological response at Month 6 is a favorable factor predictive of HBeAg loss at 2 years of entecavir therapy. Therefore, measurement of serum HBV-DNA level at 6 months of entecavir therapy is optimal to predict HBeAg loss at 2 years of therapy in HBeAg-positive CHB patients. ? 2013.
SDGs
Other Subjects
alanine aminotransferase; entecavir; hepatitis B core antigen; hepatitis B surface antigen; hepatitis B(e) antigen; antivirus agent; entecavir; guanine; hepatitis B(e) antigen; virus DNA; adolescent; adult; aged; alanine aminotransferase blood level; Article; controlled study; disease association; DNA virus; drug treatment failure; female; hepatitis B; Hepatitis B virus; human; human tissue; liver biopsy; liver cirrhosis; liver function test; major clinical study; male; multicenter study (topic); protein blood level; protein depletion; retrospective study; sample size; treatment duration; treatment response; analogs and derivatives; blood; follow up; Hepatitis B virus; Hepatitis B, Chronic; middle aged; multivariate analysis; odds ratio; prognosis; statistical model; Taiwan; treatment outcome; young adult; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Female; Follow-Up Studies; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Prognosis; Retrospective Studies; Taiwan; Treatment Outcome; Young Adult
Publisher
Elsevier B.V.
Type
journal article